REG-Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
Key Highlights
- ➤Zealand Pharma completed DKK 1.3 billion share buyback ahead of October 31 deadline
- ➤4,408,500 shares repurchased at average DKK 294.88
- ➤Treasury shares now total 5,279,342, representing approximately 7.37% of share capital
- ➤Program completed after reaching planned aggregate consideration of DKK 1,299,996,125
Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026)
Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that the share buy-back program (the "Program") initiated on May 7, 2026 has been completed. The lead manager, Danske Bank, exercised its option to close the Program ahead of October 31, 2026, after the planned aggregate amount of approximately DKK 1,300 million was reached. The Company also reports transactions under the Program for week 40 (September 28 – October 2, 2026) and week 41 (October 5, 2026).
Get started
Create a free account to read the full story.